Masiye Francis, Mayosi Bongani, de Vries Jantina
Department of Medicine, University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa.
University of Malawi College of Medicine, School of Public Health, Centre for Bioethics in Eastern and Southern Africa (CEBESA), Private Bag 360, Chichiri, Blantyre, Malawi.
BMC Med Ethics. 2017 Feb 15;18(1):12. doi: 10.1186/s12910-017-0175-z.
Advances in genetic and genomic research have introduced challenges in obtaining informed consent for research in low and middle-income settings. However, there are only few studies that have explored challenges in obtaining informed consent in genetic and genomic research in Africa and none in South Africa. To start filling this gap, we conducted an empirical study to investigate the efficacy of informed consent procedures for an H3Africa genomic study on Rheumatic Heart Disease (RHDGen) at the University of Cape Town in South Africa. The main aim of the study was to understand ethical challenges in obtaining informed consent in the RHDGen study.
We used a qualitative study methodology involving in-depth interviews and participant observations. Our study participants were RHDGen cases (patients), healthy controls and research staff involved in the recruitment of RHDGen cases and controls. In total, we conducted 32 in-depth interviews with RHDGen cases and controls, 2 in-depth interviews with research staff and 57 direct observations of the consent procedures of RHDGen cases and controls. The interviews were conducted in English, audio-recorded and transcribed verbatim. Data were analyzed using thematic content analysis. The study was conducted in 3 sites within Cape Town, South Africa.
Most healthy controls joined the RHDGen study in order to be screened for rheumatic heart disease (diagnostic misconception). A majority of RHDGen cases decided to join the RHDGen study because of therapeutic misconception.
The ethical challenges that impacted on obtaining informed consent in the RHDGen study were complex. In this study, the main challenges were diagnostic misconception among RHDGen controls and therapeutic misconception among RHDGen cases.
遗传和基因组研究的进展给在低收入和中等收入地区开展研究获取知情同意带来了挑战。然而,仅有少数研究探讨了非洲遗传和基因组研究中获取知情同意的挑战,而南非尚无此类研究。为填补这一空白,我们开展了一项实证研究,以调查南非开普敦大学一项关于风湿性心脏病的H3Africa基因组研究(RHDGen)的知情同意程序的有效性。该研究的主要目的是了解RHDGen研究中获取知情同意时面临的伦理挑战。
我们采用了定性研究方法,包括深入访谈和参与观察。我们的研究参与者包括RHDGen病例(患者)、健康对照以及参与招募RHDGen病例和对照的研究人员。我们总共对RHDGen病例和对照进行了32次深入访谈,对研究人员进行了2次深入访谈,并对RHDGen病例和对照的同意程序进行了57次直接观察。访谈用英语进行,录音并逐字转录。数据采用主题内容分析法进行分析。该研究在南非开普敦的3个地点进行。
大多数健康对照参与RHDGen研究是为了接受风湿性心脏病筛查(诊断误解)。大多数RHDGen病例决定参与RHDGen研究是因为治疗误解。
影响RHDGen研究获取知情同意的伦理挑战很复杂。在本研究中,主要挑战是RHDGen对照中的诊断误解和RHDGen病例中的治疗误解。